Supporting Information for:

In vivo two-photon imaging/excited photothermal therapy strategy of a silver-nanohybrid

Ze Huang, Li Gao, Lin Kong, Hui-Hui Zhang, Jia-Xiang Yang, Lin Li

Contents

- S1. Instruments and measurements
- S2 Characterization of silver NPs, PyAnOH and PyAnOH-Ag hybrid
- S3. Linear/nonlinear optical properties of PyAnOH and PyAnOH-Ag hybrid
- S4. Confocal co-localization studies of PyAnOH-Ag hybrid in HepG2 cells
- S5. Biodistribution of PyAnOH-Ag hybrid

S6 TP-PTT in vivo

S1 Instruments and measurements

¹H NMR, ¹³C NMR were measured on Bruker Avance 400 MHz spectrometer with tetramethylsilane (TMS) as internal standard. Mass spectra were recorded on micromass GCT-MS mass spectrometer. UV-vis absorption spectra were recorded by a Shimadzu UV-3600 spectrophotometer. The fluorescent spectra were recorded by a Hitachi F-7000 spectrometer. The FT-IR spectra are obtained on the Nexus-380 FT-IR spectrophotometer with KBr pellet as the blank, in the range of 4000-400 cm⁻¹.

For Z scan measurement, the source was an optical parametric amplifier pumped by a Ti:sapphire amplifier and tunable in the spectral range of 680 nm to 1080 nm delivering 140 fs pulses at a repetition rate of 1 kHz. The input laser beam was focused to a spot size of 1.1 mm with a 5 cm focal length convex lens. A quartz cuvette of 1 mm thickness was used to hold the sample. The sample was translated using a linear translation stage interfaced to a computer. The *fs* degenerate pump-probe experiments were performed near 740 nm for PyAnOH-DMSO solution and 840 nm for PyAnOH-Ag-DMSO suspension. The pump pulse energy was 500 mW while the probe pulse energy was 150 mW.

$$Tz = \sum_{m=0}^{\infty} \frac{[-q(z)]^m}{(m+1)^{3/2}} q(z) = \frac{\beta I_0 L_{eff}}{[1+(z/z_0)^2]\alpha}$$
(Equation 1)

Where Z_0 was the diffraction length of the beam, I_0 was the intensity of the light at focus, L_{eff} was the effective length of the sample, α was the linear absorption coefficient at the wavelength used.

$$\delta = hv\beta \times 10^{-3}/N_A d \qquad (\text{Equation } 2)$$

where *h* was the Planck's constant 6.63×10^{-34} J·s, *v* was the frequency of input intensity, N_A was the Avogadro constant 6.02×10^{-23} , and *d* was the concentration of the sample. "0 mm" is defined as light spot focus.





Figure S1. ¹H NMR spectrum of PyAnOH



Figure S2. ESI-MS spectrum of PyAnOH.



Figure S3. FT-IR spectra of PyAnOH, PyAnOH-Ag and AgNO3 respectively.



Figure S4. (a) XPS spectra for survey scan of PyAnOH, PyAnOH-Ag. XPS spectra for O_{1s} (b), Ag (c) of PyAnOH, PyAnOH-Ag. (d) XPS spectra for C_{1s} of PyAnOH-Ag

atom	Ν	0	Ag	С
atomic percentage (%)	11.2	20.2	0.18	68.42

Table S1 Atomic content in PyAnOH-Ag



Figure S5 SEM image of free PyAnOH



Figure S6 SEM image of pure Ag nanoparticle



Figure S7 The low-magnification TEM image of PyAnOH-Ag hybrid



Figure S8. (a) TEM image of PyAnOH-Ag hybrid, (b–e) the mapping images of C, N, O, Ag elements, respectively, and (f) the merge of elemental mapping image of PyAnOH-Ag hybrid with enhanced signal/noise ratio.



S3. Linear/nonlinear optical properties of PyAnOH and PyAnOH-Ag

Figure S9. (a) UV-Vis absorption and (b) Fluorescent spectra of PyAnOH $(1.0 \times 10^{-5} \text{ mol}\cdot\text{L}^{-1})$ in DMSO-H₂O mixtures with different water volume fractions. (c) The effect of water volume fraction on the maximum emission intensity and wavelength of PyAnOH in DMSO-H₂O. (c) Photographs of PyAnOH $(1.0 \times 10^{-5} \text{ mol}\cdot\text{L}^{-1})$ in daylight and under a lamp (365 nm) at DMSO-H₂O mixtures, respectively.



Figure S10. (a) UV-Vis absorption and (b) Fluorescent spectra of the molar ratio of PyAnOH (1.0 \times 10⁻⁵ mol×L⁻¹) to Ag from 1:1 to 1:10 in DMSO; (c-d) Photographs of the molar ratio of PyAnOH to Ag from 1:1 to 1:10 in daylight and under a 365 nm UV lamp, respectively.



Figure S11. DLS size profiles of PyAnOH in DMSO-H₂O mixed solvent. The water fraction is 0% (a). 40 % (b), 70 % (c) and 99 % (d), respectively.



Figure S12. DLS size profiles of PyAnOH-Ag in EtOH



Figure S13. UV-Vis absorption spectra of pure silver nanoparticles $(1.0 \times 10^{-5}-1.0 \times 10^{-4} \text{ mol}\cdot\text{L}^{-1})$ in EtOH



Figure S14. Fluorescent quantum yield of PyAnOH in DMSO



Figure S15. Fluorescent quantum yield of PyAnOH-Ag hybrid in DMSO



Figure S16. The two-photon fluorescence spectra of PyAnOH in DMSO under different excitation wavelengths



Figure S17. The two-photon fluorescence spectra of PyAnOH-Ag in DMSO under different excitation wavelengths



Figure S18. The two-photon fluorescence spectra of PyAnOH in DMSO-H₂O under different water volume fractions (f_w =0~99%).

S4. Confocal co-localization studies of PyAnOH-Ag in cells



Figure S19. Confocal co-localization studies of PyAnOH-Ag



Figure S20 (a-b) Confocal images of two-photon fluorescence and confocal bright field images without PyAnOH-Ag stained HepG2 cells under 840 nm irradiation treatments at different irradiation time.



Figure S21 (a-c) Confocal images of one photon fluorescence, confocal bright field and merge images of PyAnOH-Ag stained HepG2 cells under 488 nm laser irradiation treatments at different irradiation time under the dose of 10 μ mol·L⁻¹.



Figure S22 The relative intensity of TPEF emission of PyAnOH-Ag in HepG2 cells during the TP-PTT process.



Figuer S23 SPFM imaging of PyAnOH-Ag hybrid in MEF cell with different incubate time, 1 h for (a), 2 h for (b); Cytotoxicity evaluation of PyAnOH-Ag hybrid *via* live/dead assay with different incubate time, 1 h for (a), 2 h for (b).

S5. Biodistribution of PyAnOH-Ag



Figure S24. The relative Ag content before and after 10 min irradiation.



Figure S25 The blood circulation of PyAnOH-Ag in mice during 7 day post-injection



Figure S26 Biodistribution of PyAnOH-Ag measured at 7th day post-injection



Figure S27 The fluorescence imaging of healthy mice (a-b) and tumor-bearing mice (c-d) after intraperitoneally injection of PyAnOH-Ag



S6 TP-PTT in vivo

Figure S28. Thermal images of H22-modelled mice injected with PBS under the 840 nm laser irradiation.



Figure S29. Images of tumor-bearing-mice at 21th day after different treatment methods

materials	monitoring ability	tumor inhibition ratios	Ref
Gold-nanorods-siRNA	No	$79.5\% \pm 13.0\%$	S1
self-assembled IR820-			
PTX nanoparticles	Var	80.20/	53
	i es	89.370	52
Au-Ag nanourchins	No	almost 100%	S3
folic acid-Janus-type			
silver mesoporous silica nanoparticles@indocva	Yes	88.9%	S4
nine green			
S, Se-codoped carbon	No	70%	S5
dots			
Magnéli-phase titanium	No	almost 100%	S 6
UAIUES			
PyAnOH-Ag hybrid	Yes	almost 100%	this work

Table S2. Comparision of the tumor inhibition ratios of some reported materials for cancer

 phototheramal therapy

Reference:

- S1 B. K. Wang, X. F. Yu, J. H. Wang, Z. B. Li, P. H. Li, H. Y. Wang, L. Song, P. K. Chu, C. Z. Li, *Biomaterials*, 2016, **78**, 27-39.
- S2 D. Zhang, J. Zhang, Q. Li, H. L. Tian, N. Zhang, Z. H. Li, Y. X. Luan, ACS Appl. Mater. Interfaces, 2018, 10, 30092-30102.
- S3 Z. Liu, L. Cheng, L. Zhang, Z. B. Yang, Z. Liu, J. X. Fang, *Biomaterials*, 2014, 34, 4099-4107.
- S4 Z. Wang, Z. M. Chang, M. M. Lu, D. Shao, J. Yue, D. Yang, M. Q. Li, W. F. Dong. ACS Appl. Mater. Interfaces, 2017, 9, 30306-30317.
- S5 M. H. Lan, S. J. Zhao, Z. Y. Zhang, L. Yan, L. Guo, G. L. Niu, J. F. Zhang, J. F. Zhao, H. Y. Zhang, P. F. Wang, G. Y. Zhu, C. S. Lee, W. J. Zhang, *Nano Res.*, 2017, **10**, 3113-3123.
- S6 G. Ou, Z. W. Li, D. K. Li, L. Cheng, Z. Liu, H. Wu, Nano Res., 2016, 9, 1236-1243.